INS and obesity due to melanocortin 4 receptor deficiency: This is an exciting feature of the association of reduced MEST and ATE with improved glucose/insulin metabolism because, unlike many other anti-obesity therapies, it provides encouragement that targeting the MEST pathway to reduce ATE may have a minimal number of side effects.